Skip to content
Psychiatrist.com Logo
  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Advanced Search

Menu

  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Sign in Subscribe

Clinical Topics

View All
  • Addiction
  • ADHD
  • Alzheimer’s Disease
  • Anxiety
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Neurology
  • OCD
  • Psychopharmacology
  • PTSD and Trauma
  • Schizophrenia/Schizoaffective Disorders
  • Sleep
  • Tardive Dyskinesia
  • View All

Collections

View All
  • Academic Highlights
  • Auvelity: Information from Industry
  • Banner Alzheimer’s Institute
  • Clinical & Practical Psychopharmacology
  • Early Career Psychiatrists
  • Focus on Childhood and Adolescent Mental Health
  • Focus on Geriatric Psychiatry
  • Focus on Psychotherapy
  • Focus on Suicide
  • Focus on Psychosis
  • Focus on Women’s Mental Health
  • Rounds in the General Hospital
  • UZEDY: Information from Industry
  • View All
Back to top Open menu arrow
Download PDF Reprints
No sections available

The Journal of
Clinical Psychiatry

Free access
Bipolar Disorder

Letter to the Editor September 15, 2003

Underdiagnosis of Bipolar II Disorders in the Community

Franco Benazzi, MD

J Clin Psychiatry 2003;64(9):1130-1131

Article Abstract

Letter to the Editor

Underdiagnosis of Bipolar II Disorders in the Community

 

About the Authors

  • Franco Benazzi, MD
    View full profile
Download Free PDF

This PDF is free for all visitors!

Related News Articles

Smart Patch Offers Breakthrough in Bipolar Disorder Monitoring How Patients Talk May Matter More Than What They Say AI Predicts Schizophrenia Using Patient Records

Sponsored

PsychCase360: Choosing the Right Long-Acting Injectable for Patients With Schizophrenia
Explore two real-world schizophrenia cases with Roueen Rafeyan, MD and Melissa Vitale, PMHNP as they discuss challenges with medication adherence, transitioning to long-acting injectables (LAIs), and personalizing treatment strategies to improve patient outcomes.

Related JCP Articles

Beyond the Boxed Warning: A Call for Regulation of Psychiatry’s Most Teratogenic Drug Effects of Interpersonal and Social Rhythm Therapy on Suicidal Ideation in Adults with Bipolar II Depression Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report

Related PCC Articles

Imipramine-Induced Catatonia Bipolar Disorder Preceding PTC Diagnosis Readability of Bipolar Disorder Measures
Cover of The Journal of Clinical Psychiatry, September 2025 issue, featuring article titles on postpartum distress, aripiprazole monohydrate injectables for schizophrenia and bipolar disorder, and other psychiatric topics.

Vol 86 • 2025 • Number 3

Read the Current Issue

Original Research

Treatment Use and Preference in a Diverse Sample of Women With Mood Disorders

Original Research

Klotho and Matrix Metalloproteinase-9 Levels and Their Association with Inhibitory Dyscontrol in Adolescents with First-Episode Major Affective Disorders

Original Research

Niacin-Induced Response in Early Psychosis

Original Research

Early Ketamine Response Reduces Suicidal Events at 3 Months

Letter to the Editor

Suicide Risk among Patients with Bipolar Disorder: Sleep Disruption versus Benzodiazepine Use

Original Research

Effect of Nature Videos on the Burden of Caregivers of Patients with Dementia

View current Issue

Related Articles

JCP
Letter to the Editor

Antidepressant Effects of Combined Mood Stabilizers May Account for High Placebo Response Rates

June 22, 2021

Dr Terao comments on the methodology of a recent study evaluating citalopram for bipolar depression.
Takeshi Terao
JCP
Letter to the Editor

Antidepressants Added Nothing to Mood Stabilizers Alone: Reply to Terao

June 22, 2021

Dr Ghaemi responds to Dr Terao’s letter regarding a study of citalopram for bipolar depression.
S. Nassir Ghaemi
JCP
Letter to the Editor

Adjunctive Mood Stabilizers Are Not the Same As a Placebo-Only Arm in Bipolar Depression Trials: Reply to Terao

June 22, 2021

Dr Goldberg responds to Dr Terao’s letter regarding a study of citalopram for bipolar depression.
Joseph F. Goldberg

Watch the New PsychCase360

Explore two real-world schizophrenia cases
Promotional banner for a video titled “Choosing the Right LAI for Patients With Schizophrenia” featuring headshots of Roueen Rafeyan, MD, and Melissa Vitale, PMHNP, with a “Watch Now” button.

Subscribe to read
more articles

Subscribe
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

ELSEWHERE:

  • ABOUT
  • ADVERTISERS
  • MEDIA RELATIONS
  • REPRINTS & PERMISSIONS
  • CONTACT US
  • CUSTOMER SUPPORT

FOLLOW US:

  • X
  • FACEBOOK
  • INSTAGRAM
  • LINKEDIN
  • SIGN IN

  • JOIN THE EMAIL LIST


SUBSCRIBE NOW
An image of the Psychiatrist.com logo mark
  • Privacy Policy
  • Terms of Use
  • Physicians Postgraduate Press, Inc.
  • JCP ISSN: Online 1555-2101, Print 0160-6689
  • PCC ISSN: Online 2155-7780, Print 2155-7772
  • MedFair.com US Patent No. 684794
  • © Copyright 2025 | Physicians Postgraduate Press, Inc. | LifeLong Learning For Clinicians
  • Sitemap